121 related articles for article (PubMed ID: 37356667)
1. Reply to: RAAS inhibitors in COVID-19: Not all are created equal!
Gonçalves J; Santos CD; Fresco P; Fernandez-Llimos F
Rev Port Cardiol; 2023 Sep; 42(9):817-818. PubMed ID: 37356667
[No Abstract] [Full Text] [Related]
2. Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one.
Gonçalves J; Santos CD; Fresco P; Fernandez-Llimos F
Rev Port Cardiol; 2024 Apr; 43(4):221-222. PubMed ID: 37918782
[No Abstract] [Full Text] [Related]
3. RAAS inhibitors in COVID-19: They are not all the same!
Kow CS; Ramachandram DS; Hasan SS
Rev Port Cardiol; 2023 Sep; 42(9):815-816. PubMed ID: 37353197
[No Abstract] [Full Text] [Related]
4. Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19.
Kutz A; Conen A; Gregoriano C; Haubitz S; Koch D; Domenig O; Bernasconi L; Mueller B; Schuetz P
Eur J Endocrinol; 2021 Apr; 184(4):543-552. PubMed ID: 33539316
[TBL] [Abstract][Full Text] [Related]
5. [Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].
Limbourg FP
MMW Fortschr Med; 2020 May; 162(9):67-69. PubMed ID: 32405833
[TBL] [Abstract][Full Text] [Related]
6. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
Mancia G
Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
[No Abstract] [Full Text] [Related]
7. Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.
Loader J; Lampa E; Gustafsson S; Cars T; Sundström J
J Am Heart Assoc; 2021 Aug; 10(15):e021154. PubMed ID: 34320843
[TBL] [Abstract][Full Text] [Related]
8. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Ingraham NE; Barakat AG; Reilkoff R; Bezdicek T; Schacker T; Chipman JG; Tignanelli CJ; Puskarich MA
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341103
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 and hypertension.
Ravichandran B; Grimm D; Krüger M; Kopp S; Infanger M; Wehland M
Physiol Rep; 2021 Jun; 9(11):e14800. PubMed ID: 34121359
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
Pirola CJ; Sookoian S
J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
[TBL] [Abstract][Full Text] [Related]
11. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19).
Albashir AAD
South Med J; 2021 Jan; 114(1):51-56. PubMed ID: 33398362
[TBL] [Abstract][Full Text] [Related]
12. What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.
Wong SY; Brubaker AL; Wang AX; Taiwo AA; Melcher ML
Clin Transplant; 2020 Jul; 34(7):e13991. PubMed ID: 32446267
[TBL] [Abstract][Full Text] [Related]
13. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
[TBL] [Abstract][Full Text] [Related]
14. RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one.
Rothlin RP; Pelorosso F; Duarte M; Nicolosi L; Fernandez Criado I; Salgado MV; Vetulli H
Rev Port Cardiol; 2024 Apr; 43(4):219-220. PubMed ID: 37940073
[No Abstract] [Full Text] [Related]
15. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
Loader J; Taylor FC; Lampa E; Sundström J
J Am Heart Assoc; 2022 Jun; 11(11):e025289. PubMed ID: 35624081
[TBL] [Abstract][Full Text] [Related]
16. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
[TBL] [Abstract][Full Text] [Related]
17. Is the prognosis of non-hypertensive, COVID-19 patients treated with renin-angiotensin-aldosterone system inhibitors more uncertain?
García Martínez JJ; Wozniak H; Salamin P; Giraud R; Le Terrier C; Bendjelid K
Physiol Rep; 2022 Nov; 10(22):e15512. PubMed ID: 36397298
[TBL] [Abstract][Full Text] [Related]
18. RAAS blockers in hypertension posing a higher risk toward the COVID-19.
Singh Y; Gupta G; Satija S; Negi P; Chellappan DK; Dua K
Dermatol Ther; 2020 Jul; 33(4):e13501. PubMed ID: 32359088
[No Abstract] [Full Text] [Related]
19. Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.
Tsampasian V; Corballis N; Vassiliou VS
Curr Hypertens Rep; 2022 Oct; 24(10):425-433. PubMed ID: 35716247
[TBL] [Abstract][Full Text] [Related]
20. [Renin-angiotensin-aldosterone system : brief history and questions related to the COVID-19 pandemic].
Valdes-Socin H; Jouret F; Vroonen L; Scheen AJ; Lancellotti P
Rev Med Liege; 2020 Sup; 75(S1):123-129. PubMed ID: 33211434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
